1.
Thaci D, Menter A, Wu JJ, Arikan D, Kupper H, Bereswill M, Valdecantos WC. Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry. J of Skin [Internet]. 2017Oct.27 [cited 2020Dec.5];1(3.1):s22. Available from: https://jofskin.org/index.php/skin/article/view/79